KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)

Historic Preferred Stock Liabilities for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Q1 2021 value amounting to $448.3 million.

  • Recursion Pharmaceuticals' Preferred Stock Liabilities changed N/A to $448.3 million in Q1 2021 from the same period last year, while for Mar 2021 it was $448.3 million, marking a year-over-year change of. This contributed to the annual value of $448.3 million for FY2020, which is N/A changed from last year.
  • As of Q1 2021, Recursion Pharmaceuticals' Preferred Stock Liabilities stood at $448.3 million.
  • Recursion Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $448.3 million for Q4 2020, and its period low was $448.3 million during Q4 2020.